ICFL 2019, Berlin - Program


Thursday, 27 June 2019

16:00 – 18:20


Welcome address


Keynote Lecture:

"What is NAFLD - NASH and how it is defined"

Speaker: TBD


Keynote Lecture:

"Global Epidemiology & Outcomes of the NAFLD"

Speaker: Zobair Younossi (USA)



"Should I be looking for NASH in my clinic?"

 Jerome Boursier (France)




Debate, open discussion and Vote

Networking Reception



Friday, 28 June 2019

08:00 – 08:45
Morning Networking
08:45 – 09:15

Keynote lecture: "Biomarkers in NAFLD - If not a biopsy, what - and why

Speaker: Quentin Anstee (UK)

09:15 – 11:00






Session 1: What tools do we have to assess disease severity in NAFLD


Blood Tests


"Routine blood tests and Simple Scores in NAFLD"

Speaker: Salvatore Petta (Italy)


"New Technologies: Metabolomics, Genomics & Collagen Biomarkers"

Speaker: Detlef Schuppan (Germany)

MRI and Ultrasound


"How to use imaging to evaluate NASH in the clinic – practical approaches for use in the real world?"

Speaker: Manuel Romero Gomez (Spain)


"Ultrasound-based elastography techniques: TE, ARFI & SSI"

Speaker: Laurent Castera (France)


"MR-based assessment of inflammation and fibrosis"

Speaker: TBC


Panel Discussion

11:15 – 11:45Coffee break, Exhibition & Poster Viewing

11:45 – 13:15











Session 2: Screening - How should I evaluate NASH in my Clinic?  


Gastro/Hepatologist perspective  

Speaker: TBC


Diabetes perspective

Speaker: Gianluca Perseghin (Italy)


Case presentation


Panel discussion/ Q&A

13:15 – 14:15

Lunch, Exhibition & Poster Viewing

14:15 – 16:00











Session 3: Treating the Metabolic Syndrome in patients with NAFLD


Medical Therapy for T2DM

Speaker: Michael Roden (Germany)


Medical Therapy for Dyslipidaemia

Speaker: TBC


Case presentation


Panel discussion/Q&A

16:00 – 16:30Coffee Break, Exhibition & Poster Viewing

16:30 – 18:30








Session 4: Treating NAFLD in patients with the Metabolic Syndrome: Current Options


"Dietary Management"

Speaker: Shiri Zelber Sagi (Israel)


"Alcohol in NAFLD: an oxymoron or an important cofactor?"

Speaker: Philip Newsome (UK)


"Current available pharmacological therapeutic options for NAFLD using drugs available today"

Speaker: Kris Kowdley (USA)


"Bariatric surgery for NAFLD"

Speaker: Sebastian Mueller (Germany)


Case presentation


Panel discussion/Q&A

"Meet with the Professor" Reception


Saturday, 29 June 2019

08:00 – 08:45
Morning Networking

08:45 – 10:30




Session 5: Therapeutics Horizon Scanning: Treating NAFLD Tomorrow


Keynote Lecture:

"NAFLD Pathophysiology: Targets for Novel Treatments"

Speaker: Frank Tacke (Germany)


Drug Targets in Phase 2/3 Trials – evidence base and status update


"Bile acid signaling pathways (FXR/FGF19)" 

Speaker: Michael Trauner (Austria)


"Metabolic Pathways: Insulin Signaling, PPARs, THRb 2"

Speaker: TBC


"Trials targeting fibrosis"

Speaker: Jörn Schattenberg (Germany)


Panel Discussion/Q&A

10:30 – 11:00Coffee Break, Exhibition & e-Poster Viewing

11:00 – 13:00










Session 6: Drug development overview & Clinical Pharmacology in Practice


Keynote Lecture:

"Why too many strategies are failing and do not continue?"

Arun Sanyal (USA)


Keynote Lecture:

"The advantages of NASH patients of participating in clinical trials"

Rifaat Safadi (Israel)


"DILI in NAFLD: How to assess if a NASH drug is causing liver injury"

Speaker: Guru Aithal (UK)


Panel discussion/Q&A

13:00 – 14:30Lunch Break, Exhibition & e-Poster Viewing

14:30 – 16:15


Session 7: NAFLD & Malignancy


"Mechanisms of obesity and NASH related carcinogenesis" 

Speaker: Mathias Heikenwalder (Germany)


"HCC Surveillance in NAFLD – who, how and should you?"

Speaker: Helen Reeves (UK)


"Extra-hepatic malignancies in NAFLD" 

Speaker: Elisabetta Bugianessi (Italy)


Case presentation

Panel discussion/Q&A 

16:15 – 16:45Summing up & Closing Remarks
16:45 - 17:30Informal Discussions and Q&A with Faculty over tea/coffee

Keep Me Updated

​​​ ​​​​​ ​​​​​ ​​​​​